TIBSOVO® (Ivosidenib)

The FDA on October 24, 2023, approved TIBSOVO® for adult patients with Relapsed or Refractory MyeloDysplastic Syndromes (MDS) with a susceptible Isocitrate DeHydrogenase-1 (IDH1) mutation, as detected by an FDA-approved test. TIBSOVO® is a product of Servier Pharmaceuticals LLC.